A Proof-of-Concept Study Evaluating EOM613 in COVID-19 Infected Patients With Severe Symptoms
Status:
Recruiting
Trial end date:
2022-03-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of
EOM613, a peptide nucleic acid with novel immune-modulating properties, in treating patients
with severe COVID-19 infections. This proof-of-concept study is the first clinical trial of
EOM613 in this patient population.